Literature DB >> 3187321

Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae.

D E Briles1, J Yother, L S McDaniel.   

Abstract

Pneumococcal surface protein A (PspA) is a cell-surface protein of Streptococcus pneumoniae that is present on a number of clinical isolates as well as on the nonencapsulated laboratory strain Rx1. PspA was originally identified by monoclonal antibodies that can protect mice against intravenous challenge with some pneumococcal strains. A gene, pspA, required for the production of PspA was inactivated with use of insertional inactivation. By immunizing CBA/N (Xid) mice with congenic PspA+ and PspA- pneumococci, it was possible to demonstrate that PspA can elicit protective antipneumococcal antibodies. This result may be significant to future vaccine research, since Xid mice, like children, are not responsive to the present pneumococcal vaccine. When pspA was inactivated in three virulent, encapsulated strains of pneumococci, all three strains showed a reduction in virulence and two became totally avirulent: the 50% lethal dose was less than 10 colony-forming units (cfu) for the parents and greater than 5 x 10(4) cfu for the PspA- mutants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3187321     DOI: 10.1093/cid/10.supplement_2.s372

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  31 in total

1.  The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin.

Authors:  P Balachandran; S K Hollingshead; J C Paton; D E Briles
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

2.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Confirmation of psaA in all 90 serotypes of Streptococcus pneumoniae by PCR and potential of this assay for identification and diagnosis.

Authors:  K E Morrison; D Lake; J Crook; G M Carlone; E Ades; R Facklam; J S Sampson
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 4.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

5.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

6.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 8.  Molecular biology and respiratory disease. 6. Modern molecular biology and respiratory bacterial infections: a revolution on the horizon.

Authors:  T F Murphy
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

Review 9.  Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors:  Richard Malley; Porter W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

10.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.